脊髓性肌肉萎縮症治療市場（按治療類型、疾病類型和最終用戶分類）—2025-2032 年全球預測

預計到 2032 年脊髓性肌肉萎縮症治療市場將成長 60 億美元，複合年成長率為 15.84%。

了解脊髓性肌肉萎縮症治療的現狀，因為快速的科學技術創新不斷改善治療途徑並提高相關人員的期望

脊髓性肌肉萎縮症 (SMA) 呈現出緊迫的臨床和商業性前景，這得益於快速的科學進步和不斷演變的治療標準。該疾病的遺傳病因和獨特的病理機制催生了一系列創新治療方法，將人們的注意力從單純的支持性治療轉向持久的緩解疾病干預措施。本簡介概述了目前的治療情勢，其中新生兒篩檢的引入、早期診斷以及不斷擴展的分子治療方法正在改變患者的治療結果和臨床決策。

在過去十年中，治療方法已多樣化，包括基於載體的基因療法、反義寡核苷酸以及調節SMN2剪接的口服小分子化合物，並輔以旨在維持功能和生活品質的綜合支持治療。同時，相關人員的期望也日趨成熟：臨床醫生要求可靠的長期安全性數據，相關人員尋求將臨床效益與永續價值聯繫起來的證據，製造商則優先考慮可擴展的生產和全球供應彈性。因此，本節將深入探討SMA亞型的結構性變化、政策影響和臨床細微差別，以及決定治療藥物如何在不同醫療環境中惠及病患的營運考量。

隨著法律規範不斷調整，以適應一次性且使用頻率較低的先進療法，神經病學、遺傳學、加護治療和居家照護服務之間的多學科合作將至關重要。本報告的核心是不斷發展的臨床實踐、報銷模式和物流在現實世界中的相互作用，旨在為領導者提供解讀下游分析和實施切實可行的策略所需的背景資訊。

繪製重塑脊髓性肌肉萎縮症治療途徑中治療選擇和價值再形成基礎設施的關鍵轉型變化

在突破性科學、臨床試驗擴展和醫療服務模式轉變的推動下，SMA 治療領域正在經歷變革性變革。基因療法的引入徹底改變了人們對早期潛在治癒性干預措施的期望，促使醫療系統和醫療服務提供者整合新生兒篩檢和快速轉診途徑，以充分利用時間敏感性療效。同時，SMN2 標靶療法和口服調變器的成熟拓寬了治療套件，為早發和晚發性疾病提供了差異化治療方案，同時也需要細緻的患者選擇和縱向監測策略。

同時，臨床實踐正轉向多學科護理模式，將藥物治療與呼吸、營養和復健支持相結合，以最大限度地提高功能效益。真實世界證據的產生和登記對於理解異質性患者群體的長期安全性和持久性至關重要，而付款人和衛生技術評估組織則強調基於結果的安排和風險分擔機制，以使支付與永續效益保持一致。諸如製程強化和分散式供應鏈解決方案等製造創新正在興起，旨在解決生技藥品和基因治療製造的複雜性和低溫運輸要求。最終，臨床、監管和營運變革的整合正在創建一個生態系統，該生態系統獎勵敏捷性、證據生成和夥伴關係，從而將臨床開發與以患者為中心的獲取途徑連接起來。

評估 2025 年關稅對 SMA 治療供應鏈製造選擇和患者連續性的連鎖營運監管和存取影響。

2025年實施的關稅和貿易政策調整，為參與先進脊髓性肌肉萎縮症（SMA）療法研發、生產和分銷的相關人員帶來了額外的複雜性。影響原料藥、病毒載體、一次性生物製程設備和低溫運輸供應的關稅措施，可能會增加到岸成本，並使製造商和醫療保健系統的採購時間表複雜化。此類政策轉變也促使製造商重新評估其全球製造地，考慮在地化生產，並擴大對供應鏈冗餘的投資，以減輕進口關稅和貿易中斷的風險。

作為回應，許多申辦者正在加快關鍵部件的在地化策略，並尋求反映生物製藥治療和臨床重要性的關稅分類和豁免。醫療保健組織和專業藥房正在重新評估採購合約、儲存能力和分銷合作夥伴，以便在供應成本上升的情況下保持患者能夠獲得藥物。此外，關稅可能會影響組合產品的經濟性，例如將基因治療與專門的住院服務捆綁在一起，並可能影響付款人談判，因為報銷模式對藥品採購成本的變化很敏感。從臨床營運的角度來看，對進口診斷劑和設備配件的監管依賴可能會改變臨床實驗緊急時應對計畫，臨床實驗替代供應商和前瞻性庫存管理。總之，2025 年的關稅環境凸顯了協調製造、監管和商業計劃的策略必要性，以保持彈性並確保患者護理的連續性。

確定治療方式、疾病表現型和護理環境如何相互交叉，以推動差異化的臨床方法和商業化策略

細分主導的洞察揭示了不同治療方式、疾病表現型和護理環境之間的細微動態，這些動態會影響臨床決策和商業策略。根據治療類型，市場分別檢視基因治療、SMN2標靶治療和支持性治療，每種治療都呈現獨特的發展路徑、製造需求和證據產生需求，進而影響商業化時間表和臨床應用。另一方面，SMN2標靶治療強調重複給藥方案、依從性平台和口服給藥的機會，以擴大門診管理。支持性治療仍然是維持功能和生活品質的核心治療方法，通常與藥物介入相結合，形成一個由臨床醫生進行整體評估的綜合護理方案。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

• 脊髓性肌肉萎縮症的下一代基因治療方法的進展
• 口服小分子剪接調節劑的出現改善了 SMA 患者的治療機會
• 現實世界的療效和長期安全性數據將推動 SMA 治療的付款人報銷決策
• 開發SMN獨立路徑的聯合治療，以增強SMA的神經保護作用
• 擴大新生兒篩檢工作將有助於對 SMA 進行症狀前治療，提高存活率。
• 即將上市的生物相似藥對全球 SMA 市場中 Nusinersen 定價和市場進入的影響
• 整合遠端醫療監控平台，最佳化脊髓性肌肉萎縮症的長期管理

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章脊髓性肌肉萎縮症治療市場（依治療類型）

• 基因治療
• SMN2標靶治療
• 支持性護理

第9章脊髓性肌肉萎縮症治療市場（依疾病類型）

• 類型 1
• 類型 2
• 類型 3
• 類型 4

第 10 章脊髓性肌肉萎縮症治療市場（依最終使用者）

• 居家照護環境
• 醫院
• 專科診所

第11章脊髓性肌肉萎縮症治療市場（按地區）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第12章脊髓性肌肉萎縮症治療市場（依類別）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第13章脊髓性肌肉萎縮症治療市場（依國家）

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第14章競爭格局

• 2024年市佔率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • Biogen Inc.
  • Novartis AG
  • Roche Holding AG
  • Ionis Pharmaceuticals, Inc.
  • PTC Therapeutics, Inc.
  • Biohaven, Ltd.
  • NMD PHARMA A/S
  • Cytokinetics
  • Biohaven, Ltd.
  • Genzyme Corporation

The Spinal Muscular Atrophy Treatment Market is projected to grow by USD 6.00 billion at a CAGR of 15.84% by 2032.

Contextualizing the contemporary spinal muscular atrophy therapeutic landscape amid rapid scientific innovation evolving care pathways and stakeholder expectations

Spinal muscular atrophy (SMA) presents an urgent clinical and commercial landscape defined by rapid scientific progress and evolving standards of care. The disorder's genetic etiology and distinct disease types have guided a wave of innovative therapeutic approaches, shifting attention from purely supportive measures toward durable, disease-modifying interventions. This introduction frames the contemporary context where newborn screening adoption, earlier diagnosis, and a growing repertoire of molecular therapies converge to transform patient outcomes and clinical decision-making.

Over the past decade, treatment modalities have diversified to include vector-based gene therapies, antisense oligonucleotides, and orally administered small molecules that modulate SMN2 splicing, complemented by comprehensive supportive care aimed at preserving function and quality of life. Simultaneously, stakeholder expectations have matured: clinicians seek robust long-term safety data; payers demand evidence linking clinical benefit to sustainable value; and manufacturers prioritize scalable manufacturing and global supply resilience. Therefore, this section sets the stage for a detailed review of structural shifts, policy influences, clinical nuances across SMA types, and the operational considerations that will determine how therapies reach patients in diverse care settings.

As regulatory frameworks adapt to accommodate one-time and infrequently administered advanced therapies, cross-disciplinary coordination among neurology, genetics, intensive care, and homecare services becomes essential. The interaction between evolving clinical practice, reimbursement models, and logistical realities will be the central thread of this report, offering leaders the context necessary to interpret downstream analyses and implement pragmatic strategies.

Mapping the pivotal transformative shifts reshaping therapy selection delivery infrastructure and value realization across spinal muscular atrophy care pathways

The SMA treatment landscape has undergone transformative shifts driven by breakthrough science, expanded testing, and changing care delivery models. Gene therapy introductions have reframed expectations of early, potentially curative interventions, prompting health systems and providers to integrate newborn screening and rapid referral pathways to capitalize on time-sensitive efficacy. In parallel, the maturation of SMN2-targeted therapies and orally administered modulators has broadened the therapeutic toolkit, creating differentiated options for early-onset and later-onset disease while also necessitating nuanced patient selection and longitudinal monitoring strategies.

Concurrently, clinical practice has migrated toward multidisciplinary care models that combine pharmacologic treatment with respiratory, nutritional, and rehabilitative support to maximize functional gains. Real-world evidence generation and registries have become critical to understanding long-term safety and durability across heterogeneous patient populations, while payers and health technology assessment bodies emphasize outcomes-based arrangements and risk-sharing mechanisms to align payment with sustained benefit. Manufacturing innovations, including process intensification and decentralized supply chain solutions, are emerging to address production complexity and cold-chain requirements for biologics and gene therapies. Ultimately, this confluence of clinical, regulatory, and operational changes has created an ecosystem that rewards agility, evidence generation, and partnerships that bridge clinical development with patient-centered access pathways.

Assessing the cascading operational regulatory and access consequences of 2025 tariff actions on supply chains manufacturing choices and patient continuity for SMA therapies

The imposition of tariffs and trade policy adjustments in 2025 has introduced additional layers of complexity for stakeholders involved in the development, manufacture, and distribution of advanced SMA therapies. Tariff measures that affect active pharmaceutical ingredients, viral vectors, single-use bioprocessing equipment, and cold-chain supplies can increase landed costs and complicate procurement timelines for manufacturers and health systems. These policy shifts also incentivize manufacturers to reassess global manufacturing footprints, consider regionalization of production, and amplify investment in supply chain redundancy to mitigate exposure to import duties and trade disruptions.

In response, many sponsors are accelerating localization strategies for critical components and seeking tariff classifications or exemptions that reflect the therapeutic and clinical importance of biologic materials. Health systems and specialty pharmacies are reevaluating procurement contracts, storage capacity, and distribution partners to preserve patient access amid higher supply costs. Furthermore, tariffs can affect the economics of combination offerings-such as gene therapy administration bundled with specialized inpatient services-and influence payer negotiations where reimbursement models are sensitive to changes in drug acquisition costs. From a clinical operations perspective, regulatory reliance on imported diagnostic reagents or device accessories may alter trial timelines and site readiness, prompting contingency planning that integrates alternative suppliers and forward-looking inventory management. Collectively, the 2025 tariff environment underscores the strategic imperative of aligning manufacturing, regulatory, and commercial planning to preserve resilience and protect patient continuity of care.

Illuminating how treatment modalities disease phenotypes and care environments intersect to drive differentiated clinical approaches and commercialization strategies

Segmentation-driven insights reveal nuanced dynamics across distinct therapeutic modalities, disease phenotypes, and care settings that influence clinical decision-making and commercial strategy. Based on Treatment Type, market is studied across Gene Therapy, SMN2-Targeted Therapy, and Supportive Therapy, each presenting unique development pathways, manufacturing demands, and evidence-generation needs that shape commercialization timelines and clinical adoption. Gene therapies require concentrated attention on one-time administration logistics, long-term follow-up commitments, and manufacturing scale-up, whereas SMN2-targeted therapies emphasize iterative dosing regimens, adherence infrastructure, and the opportunity for oral administration to expand outpatient management. Supportive therapies remain central to preserving function and quality of life and frequently intersect with pharmacologic interventions, creating integrated care packages that clinicians evaluate holistically.

Based on Disease Type, market is studied across Type 1, Type 2, Type 3, and Type 4, and each phenotype demands tailored clinical endpoints, timing of intervention, and caregiver education strategies. Type 1 patients typically require urgent pathways and early intervention to prevent rapid decline, whereas Types 2 through 4 present a spectrum of progression where functional milestones and respiratory outcomes guide treatment choices. Based on End User, market is studied across Homecare Settings, Hospitals, and Specialty Clinics, each offering distinct delivery models, reimbursement mechanisms, and workforce competencies. Homecare adoption accelerates patient-centered care and maintains continuity for chronic dosing, hospitals provide intensive administration and acute management, and specialty clinics concentrate expertise, multidisciplinary coordination, and registry-based follow-up. Integrating these layers of segmentation into program planning allows stakeholders to design tailored value propositions, optimize resource allocation, and anticipate distinct operational barriers across patient cohorts and care venues.

Decoding regional variations in regulatory pathways procurement infrastructure and care capacity that determine access and implementation strategies across global SMA markets

Regional insights highlight how geopolitical, regulatory, and healthcare delivery variations shape access, clinical adoption, and infrastructure investment across key geographies. In the Americas, the landscape is characterized by robust investment in novel therapeutics, rapid uptake where reimbursement pathways are established, and significant emphasis on value-based contracting that ties payment to demonstrated outcomes and long-term follow-up data. Systems in this region often support advanced cold-chain logistics and specialized infusion centers, but they also face payer scrutiny and price negotiation complexities that require comprehensive health economic dossiers.

In Europe, Middle East & Africa, regulatory harmonization across multiple authorities, variable reimbursement timelines, and heterogeneous healthcare capacity create both opportunities and barriers. Some markets prioritize early adoption through centralized procurement or national access agreements, while others require incremental evidence from local registries. Capacity constraints for specialized administration and cold-chain maintenance in certain jurisdictions emphasize the need for adaptive delivery models and public-private partnerships to scale care. In the Asia-Pacific region, rapid expansion of newborn screening programs, growing domestic manufacturing capabilities, and an increasing focus on public reimbursement frameworks are reshaping access dynamics. Local production incentives and diverse payer landscapes drive manufacturers to adopt tiered strategies that balance centralized manufacturing with regional supply solutions and targeted engagement with national health authorities. Understanding these regional distinctions enables stakeholders to align clinical development, market entry sequencing, and supply chain design with localized needs and regulatory expectations.

Uncovering the organizational priorities and collaborative approaches that enable successful development scale-up and sustained market access for SMA therapeutic programs

Key company-level insights emphasize the strategic choices that separate successful program execution from stalled initiatives in a complex therapeutic field. Leading developers of advanced therapies have concentrated on securing manufacturing maturity, establishing long-term safety monitoring platforms, and forging partnerships with specialized providers to manage administration logistics and patient follow-up. Strategic collaborations between biologics manufacturers and contract development and manufacturing organizations accelerate process scale-up and allow originators to focus on clinical development and evidence generation. Meanwhile, companies focusing on SMN2 modulation have invested heavily in outpatient-friendly formulations and pharmacovigilance systems to support chronic administration and adherence programs.

Commercially, organizations that integrate payer engagement early and commit to real-world evidence frameworks gain negotiating leverage and smoother reimbursement pathways. Firms that proactively build registry infrastructure and longitudinal data capture demonstrate value beyond clinical trial endpoints, facilitating risk-sharing agreements and coverage-for-value arrangements. Additionally, companies investing in patient support services, remote monitoring technologies, and caregiver education reduce friction across care transitions and improve retention in long-term follow-up programs. Finally, strategic geographic partnerships and localized manufacturing or fill-finish arrangements have become critical levers to mitigate tariff exposure, expedite market entry, and strengthen supply reliability in a policy environment that increasingly values regional resilience.

Actionable strategic imperatives for leaders focusing on evidence generation resilient manufacturing and patient-centered delivery to secure access and long-term value

Industry leaders should orient strategy around integrated evidence generation, resilient manufacturing, and patient-centered delivery to navigate clinical complexity and policy volatility. Prioritize early and sustained engagement with payers and health technology assessors to co-design endpoints and real-world evidence plans that meet coverage criteria while reflecting meaningful patient outcomes. Concurrently, invest in scalable manufacturing platforms and regional redundancy for critical inputs to reduce exposure to tariff and trade shocks, support timely product launch, and preserve continuity of care for time-sensitive therapies.

Operationally, expanding homecare capabilities and bolstering specialty clinic networks will enable broader access to both chronic and one-time therapies while reducing system burden. Establish comprehensive patient support services that include remote monitoring, caregiver education, and adherence programs to improve outcomes and streamline long-term safety follow-up. Forge strategic partnerships with contract manufacturing and logistics providers that have proven experience with viral vectors, single-use bioprocessing, and ultra-cold-chain handling to mitigate operational risk. Finally, adopt flexible pricing and contracting models that allow for value-based elements and geographic sensitivity, recognizing that reimbursement environments and willingness-to-pay differ across regions and care settings.

Explaining the rigorous mixed-method research approach integrating primary expert interviews secondary evidence synthesis and scenario analysis to ensure actionable findings

The research methodology underpinning this analysis combined structured primary research with rigorous secondary synthesis and iterative triangulation to ensure robustness and relevance. Primary inputs included in-depth interviews with clinicians, manufacturing experts, payer representatives, and specialty pharmacy leaders to capture operational realities, clinical decision drivers, and reimbursement preferences. Secondary research encompassed peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to contextualize clinical efficacy, safety signals, and regulatory milestones. Data were synthesized through cross-validation between stakeholder perspectives and documented sources to identify consistent patterns and areas of divergence.

Analytic procedures prioritized transparency in source attribution, reproducibility of methods, and sensitivity to jurisdictional differences in regulation and care delivery. Where gaps in published evidence existed, targeted expert elicitation was used to interpret emerging clinical practice trends and to outline plausible operational scenarios. Finally, the research applied a scenario-based approach to stress-test assumptions around manufacturing capacity, supply chain disruptions, and policy shifts, ensuring that recommendations are resilient across a range of foreseeable developments and pragmatic for both public and private stakeholders.

Summarizing the strategic synthesis of clinical innovation regulatory dynamics and operational resilience required to translate SMA advances into sustained patient benefit

In conclusion, the spinal muscular atrophy treatment landscape has moved decisively from supportive management toward a spectrum of disease-modifying options that demand coordinated clinical, operational, and commercial responses. The interplay between gene therapies, SMN2-targeted agents, and supportive care requires stakeholders to align evidence-generation strategies, manufacturing scale-up, and patient-centered delivery models to realize therapeutic potential in real-world settings. Policy shifts, including tariff actions and evolving reimbursement paradigms, further underscore the importance of supply chain resilience and adaptive regional strategies to preserve access.

Moving forward, success will hinge on the ability to integrate long-term safety and effectiveness data into stakeholder conversations, to design manufacturing and distribution networks that withstand geopolitical and logistical pressures, and to develop commercial approaches that reflect heterogeneous payer expectations and care system capabilities. By centering patients in operational design and leveraging collaborative partnerships across industry, clinical care, and payers, organizations can translate scientific innovation into sustained improvements in outcomes for individuals living with SMA.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Advances in next-generation gene therapy delivery methods for spinal muscular atrophy
• 5.2. Emerging oral small-molecule splicing modulators improving treatment accessibility in SMA patients
• 5.3. Real-world effectiveness and long-term safety data fostering payer reimbursement decisions for SMA therapies
• 5.4. Development of combination therapies targeting SMN-independent pathways to enhance neuroprotective outcomes in SMA
• 5.5. Expansion of newborn screening initiatives enabling presymptomatic treatment and improved survival rates in SMA
• 5.6. Impact of upcoming biosimilar launches on pricing dynamics and market access for nusinersen in global SMA markets
• 5.7. Integration of telehealth and digital monitoring platforms to optimize long-term management of spinal muscular atrophy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Spinal Muscular Atrophy Treatment Market, by Treatment Type

• 8.1. Gene Therapy
• 8.2. SMN2-Targeted Therapy
• 8.3. Supportive Therapy

9. Spinal Muscular Atrophy Treatment Market, by Disease Type

• 9.1. Type 1
• 9.2. Type 2
• 9.3. Type 3
• 9.4. Type 4

10. Spinal Muscular Atrophy Treatment Market, by End User

• 10.1. Homecare Settings
• 10.2. Hospitals
• 10.3. Specialty Clinics

11. Spinal Muscular Atrophy Treatment Market, by Region

• 11.1. Americas
  • 11.1.1. North America
  • 11.1.2. Latin America
• 11.2. Europe, Middle East & Africa
  • 11.2.1. Europe
  • 11.2.2. Middle East
  • 11.2.3. Africa
• 11.3. Asia-Pacific

12. Spinal Muscular Atrophy Treatment Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Spinal Muscular Atrophy Treatment Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Analysis
  • 14.3.1. Biogen Inc.
  • 14.3.2. Novartis AG
  • 14.3.3. Roche Holding AG
  • 14.3.4. Ionis Pharmaceuticals, Inc.
  • 14.3.5. PTC Therapeutics, Inc.
  • 14.3.6. Biohaven, Ltd.
  • 14.3.7. NMD PHARMA A/S
  • 14.3.8. Cytokinetics
  • 14.3.9. Biohaven, Ltd.
  • 14.3.10. Genzyme Corporation

LIST OF FIGURES

• FIGURE 1. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 9. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMN2-TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMN2-TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMN2-TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMN2-TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMN2-TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SMN2-TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY REGION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 73. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 74. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 75. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 76. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 77. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 78. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 79. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 80. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 81. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 84. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 85. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 86. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 87. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 88. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 89. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 90. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 91. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 92. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 93. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 94. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 95. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 96. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 97. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 98. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 105. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 108. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 109. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 110. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 111. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 112. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 113. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 116. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 117. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 118. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 119. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 120. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 121. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 124. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 125. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 126. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 127. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 128. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 129. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 132. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 133. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 134. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 135. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 136. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 142. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 143. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 144. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 145. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 146. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 147. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 150. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 151. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 152. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 153. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 154. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 155. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 156. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 157. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 158. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 159. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 160. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 161. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 162. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 163. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 166. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 167. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 168. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 169. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 170. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 171. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 174. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 175. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 176. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 177. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 178. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 179. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 182. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 183. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 184. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 185. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 186. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 190. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 191. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 192. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 193. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 194. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 195. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 196. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 197. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 198. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 199. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 200. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 201. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 202. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 203. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 204. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 205. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 206. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 207. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 208. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 209. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 210. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 211. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 212. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 213. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 214. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 215. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 216. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 217. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 218. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 219. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 220. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 221. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 222. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 223. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 224. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 225. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 226. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 227. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 228. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 229. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 230. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 231. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 232. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 233. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 234. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 235. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 236. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 237. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 238. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 239. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 240. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 241. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 242. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 243. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 244. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 245. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 246. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 247. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 248. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 249. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 250. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 251. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 252. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 253. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 254. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 255. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 256. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 257. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 258. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 259. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 260. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 261. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 262. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 263. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 264. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 265. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 266. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 267. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 268. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 269. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 270. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 271. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 272. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 273. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 274. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 275. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 276. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
• TABLE 277. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 278. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 279. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 280. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024